Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

T lymphocyte characteristics and immune repertoires in the epicardial adipose tissue of heart failure patients

Zhang XZ., Chen XL., Tang TT., Zhang S., Li QL., Xia N.

Prospective Study on Cardiovascular Disease, published in Front Immunol (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Immunol (2023)
Reported sample size
—
Source database
Europe PMC
PMID
36960061
PMCID
PMC10027920
DOI
10.3389/fimmu.2023.1126997
Citations
11

Abstract (original English)

Background Epicardial adipose tissue (EAT) acts as an active immune organ and plays a critical role in the pathogenesis of heart failure (HF). However, the characteristics of immune cells in EAT of HF patients have rarely been elucidated. Methods To identify key immune cells in EAT, an integrated bioinformatics analysis was performed on public datasets. EAT samples with paired subcutaneous adipose tissue (SAT), heart, and peripheral blood samples from HF patients were collected in validation experiments. T cell receptor (TCR) repertoire was assessed by high-throughput sequencing. The phenotypic characteristics and key effector molecules of T lymphocytes in EAT were assessed by flow cytometry and histological staining. Results Compared with SAT, EAT was enriched for immune activation-related genes and T lymphocytes. Compared with EAT from the controls, activation of T lymphocytes was more pronounced in EAT from HF patients. T lymphocytes in EAT of HF patients were enriched by highly expanded clonotypes and had greater TCR clonotype sharing with cardiac tissue relative to SAT. Experiments confirmed the abundance of IFN-γ + effector memory T lymphocytes (T EM ) in EAT of HF patients. CCL5 and GZMK were confirmed to be associated with T lymphocytes in EAT of HF patients. Conclusion EAT of HF patients was characterized by pronounced immune activation of clonally expanded IFN-γ + T E

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
PericardiumAdipose TissueHumansReceptors, Antigen, T-CellSubcutaneous FatHeart Failure

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research